Journal article
Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial
MD Hill, M Goyal, BK Menon, RG Nogueira, RA McTaggart, AM Demchuk, AY Poppe, BH Buck, TS Field, D Dowlatshahi, BA van Adel, RH Swartz, RA Shah, E Sauvageau, C Zerna, JM Ospel, M Joshi, MA Almekhlafi, KJ Ryckborst, MW Lowerison Show all
Lancet | Published : 2020
Abstract
Background: Nerinetide, an eicosapeptide that interferes with post-synaptic density protein 95, is a neuroprotectant that is effective in preclinical stroke models of ischaemia-reperfusion. In this trial, we assessed the efficacy and safety of nerinetide in human ischaemia-reperfusion that occurs with rapid endovascular thrombectomy in patients who had an acute ischaemic stroke. Methods: For this multicentre, double-blind, randomised, placebo-controlled study done in 48 acute care hospitals in eight countries, we enrolled patients with acute ischaemic stroke due to large vessel occlusion within a 12 h treatment window. Eligible patients were aged 18 years or older with a disabling ischaemic ..
View full abstractGrants
Awarded by Heart and Stroke Foundation of Canada
Funding Acknowledgements
Canadian Institutes for Health Research, Alberta Innovates, and NoNO.